FDA Expands Access to Breakthrough Pancreatic Cancer Therapy
Expanding Treatment Frontiers The U.S. Food and Drug Administration (FDA) has officially expanded access to daraxonrasib, a novel therapeutic agent designed to treat advanced pancreatic cancer. The agency’s decision, announced this week in Washington, D.C., follows compelling clinical data demonstrating the drug’s efficacy in patients who have exhausted traditional chemotherapy options. Former U.S. Senator Ben…